View Future GrowthThis company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsAbcam 過去の業績過去 基準チェック /06Abcamの収益は年間平均-56.5%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間33.8% 9.8%割合で 増加しています。 Abcamの自己資本利益率は0.3%であり、純利益率は0.7%です。主要情報-56.52%収益成長率-57.50%EPS成長率Biotechs 業界の成長17.04%収益成長率9.84%株主資本利益率0.35%ネット・マージン0.66%前回の決算情報30 Jun 2023最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • Dec 19Abcam Files Form 15Abcam plc (Abcam Limited) has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Ordinary Shares, nominal value £0.002 per share and American Depositary Shares, each representing one Ordinary Share under the Securities Exchange Act of 1934, as amended.お知らせ • Dec 07+ 2 more updatesAbcam plc(NasdaqGS:ABCM) dropped from NASDAQ Composite IndexAbcam plc has been dropped from NASDAQ Composite Index .お知らせ • Oct 24Jonathan Milner Issues Statement Responding to the Glass Lewis ReportOn October 23, 2023, Jonathan Milner announced that he has issued a statement in response to a report from Glass Lewis and its observations on the disproportionate rewards for Company’s Executive Directors and on the identified issues with peer group valuation strategies. In addition, Jonathan Milner urged the shareholders to vote against the current proposed acquisition of Company by Danaher Corporation.お知らせ • Oct 20Jonathan Milner Continues Opposition to Danaher Corporation AcquisitionOn October 18, 2023, Jonathan Milner announced that he has responded to the Institutional Shareholder Services (ISS) recommendation to vote in favour of the deal. Jonathan Milner stated that he is continuing his attempts to convince shareholders to vote against Abcam plc's $5.7bn acquisition by Danaher Corporation despite a recommendation in favour by ISS. Jonathan Milner added that his reasoning remains as it was back in August - that the sale price of $24 per share is undervaluing the Company's short-term growth potential. Jonathan Milner stated that while he maintains his willingness to see the Company go to Danaher Corporation or ‘another suitor at a fair price’, the likelihood of a tall dark stranger sweeping in should this deal fall through is low.お知らせ • Oct 17Jonathan Milner Releases Presentation to Abcam plc ShareholdersOn October 16, 2023, Jonathan Milner announced that he has issued a presentation covering the reasons for Abcam shareholders to vote against the $24 per share bid from Danaher Corporation. Jonathan Milner added that he believes that the Company stands as an exceptional UK asset and should not be undersold to Danaher and mentioned that he is open to selling to Danaher or another suitor at a fair price that genuinely reflects the Company’s true value and potential. Jonathan Milner stated that, in the presentation, he has unveiled his strategy for the Company and stated that he intends to convene an Extraordinary General Meeting (EGM) aimed at overhauling the Company's Board.お知らせ • Oct 11Jonathan Milner issues Open Letter to shareholders of Abcam plcOn October 10, 2023, Jonathan Milner announced that he has issued a letter to Abcam plc’s shareholders for recently published scheme circular (Scheme Circular, as published on October 5, 2023) detailing the proposed acquisition of the Company by Danaher Corporation or its affiliates. Jonathan Milner added that he is prepared to sell to Danaher or to another bidder at the right price, provided that it accurately reflects the value and potential of the Company and stated that shareholders are not seeing the full value of the investment that the Company undertook to drive improved performance over the longer term. In addition, Jonathan Milner urged the shareholders to question the scheme circular, the unacceptable Offer price and continue to vote against the current proposed acquisition of the Company by Danaher Corporation.お知らせ • Sep 29Jonathan Milner issues Open Letter to Shareholders of Abcam plcOn September 28, 2023, Jonathan Milner announced that he has issued open letter to the Company’s shareholders announcing his vote against campaign and providing them with the opportunity to send a clear message to the Board that the board is dissatisfied with the proposed acquisition of the Company by Danaher Corporation or its affiliates (“Danaher”) and the Company’s governance, execution and cost control.お知らせ • Sep 15Jonathan Milner Opposes Danaher's Acquisition of AbcamOn September 14, 2023, Jonathan Milner announced his decision to vote against the proposed acquisition of Abcam by Danaher Corporation or its affiliates, his decision to oppose the acquisition is informed by feedback received from many shareholders and analysts, who share his belief that the $24 per share offer announced on August 28, 2023 by the Company substantially undervalues the Company, and when considering the potential of the Company as an independent entity with an effective Board and Executive Leadership, the proposed acquisition price falls significantly short of its inherent worth. In addition, Jonathan Milner stated that he will formally request the Company to convene an extraordinary general meeting with the purpose of replacing the Company’s board, including the current CEO, CFO and Chairman. Further, Jonathan Milner stated that he will publish a proxy statement and accompanying proxy card in due course to be used to solicit votes in support of the proposals that will be presented for shareholder vote at the proposed extraordinary annual meeting of stockholders of the Company.お知らせ • Sep 02Abcam plc Suspends Financial Guidance for the Fiscal 2023 and Fiscal 2024Abcam plc suspended financial guidance for the fiscal 2023 and fiscal 2024. Due to the pending acquisition, financial guidance has been suspended.お知らせ • Aug 29Danaher Corporation (NYSE:DHR) entered into definitive agreement to acquire Abcam plc (NasdaqGS:ABCM) for $5.7 billion.Danaher Corporation (NYSE:DHR) entered into definitive agreement to acquire Abcam plc (NasdaqGS:ABCM) for $5.7 billion on August 26, 2023. As per the the terms of the transaction, the offer price per share is $24 for 229,723,147 Abcam shares. Danaher expects to fund the acquisition using cash on hand and proceeds from the issuance of commercial paper. Under the Transaction Agreement, Abcam plc will be required to pay to Danaher, in cash, an amount equal to £45 million ($56.62512 million) if the transaction agreement is terminated, whereas, Danaher Corporation will pay £227 million ($285.642272 million) in case of termination. Transaction is subject to customary conditions, including receipt of applicable regulatory approvals and Abcam shareholder approval. The Transaction has been unanimously approved and recommended by the Abcam Board of Directors and unanimously approved by the Danaher Board of Directors. The transaction is anticipated to close mid-2024 . Lazard Freres & Co. LLC, Lazard & Co., Limited, Morgan Stanley & Co. International plc, acted as financial advisors and provided opinion to board of Abcam, Citibank, N.A., acted as a depository bank, Latham & Watkins (London) LLP acted as a legal advisor to Abcam. Skadden, Arps, Slate, Meagher & Flom LLP acted as a legal advisor to Danaher. Phillip R. Mills of Davis Polk advised Lazard Ltd. and Morgan Stanley as financial advisers to Abcam plc.お知らせ • Aug 17Jonathan Milner Sends an Open Letter to Abcam plcOn August 16, 2023, Jonathan Milner announced that he has sent an open letter to Abcam plc, stating that the Company had received strategic inquiries from multiple parties over the past few weeks and the Board of Directors had unanimously decided to initiate a process to explore strategic alternatives for the business. In addition, Jonathan Milner stated that in order to give the Board the time and space to pursue the opportunities from the review, and acting in good faith, he temporarily suspended his campaign and requested removal of the EGM resolutions on June 26, 2023, he was disappointed that this offer was not acted upon and since that time have been provided with one unsatisfactory call with management, and he would like to reiterate that his offer remains in place should the board wish to accept my help with Company performance and shareholder value creation.お知らせ • Jul 06Abcam plc Provides Revenue Guidance for the First Half Ending June 30, 2023Abcam plc provided revenue guidance for the first half ending June 30, 2023. For the period, the company expects revenues of >£203 million. First half 2023 estimated revenues grew approximately 10% on a reported basis or 5.5% on a constant exchange rate basis as compared to 20% growth on a constant exchange rate basis in the comparable prior period.お知らせ • Jun 29Jonathan Milner Announces Suspension of Proxy SolicitationOn June 26, 2023, Jonathan Milner issued a statement regarding the upcoming extraordinary meeting of shareholders of Abcam PLC. Jonathan Milner stated that in light of reports that the Company has received credible inbound M&A interest, and the Company’s announcement that the board is pursuing these strategic alternatives, he has decided to suspend his solicitation for the time being to allow the board to focus on pursuing its strategic review and thereby create maximum shareholder value. Jonathan Milner added that he remains willing to join the board immediately, either as Executive Chairman, Chairman or a Non-Executive Director, if invited to assist and support it in the strategic review process to obtain a full and fair price but will not agree to any standstill restrictions that would impair his ability to hold the board accountable by calling for another EGM or nominating directors at the next AGM.お知らせ • Jun 28Abcam plc Provides Revenue Guidance for Fy2023 and Fy2024Abcam plc provided revenue guidance for FY2023 and FY2024. The Company reiterates its FY2023 guidance of reported revenue of approximately £420 million to £440 million, representing 15% to 20% constant exchange rate revenue growth.For FY2024, reported revenue of approximately £475 million to £525 million1, representing 11.3% to 13.4% CER revenue CAGR2 and 10.0% to 12.1% organic revenue CAGR3 from FY2019.お知らせ • Jun 22Jonathan Milner Issues an Open Letter to shareholders of Abcam plcOn June 21, 2023, Jonathan Milner announced that he has issued an open letter to shareholders of Abcam plc, in response to statements made by the Company in its statement on 20 June 2023, outlines the Company’s lack of focus and his plan to restore the Company’s financials, accountability, and executional discipline. In addition, Jonathan Milner stating that as a reminder the deadline for ADS shareholders to record your proxy vote is 10am EST on6 July 2023, stated it his open letter that time for change is now, the Company interest in M&A, his 6-month plan for Company’s value creation. Further, Jonathan Milner urged the shareholders to vote for removal of Peter Allen, Michael Baldock, and Sally Crawford, from the Company board, election of Jonathan Milner as a Director and appointment as Executive Chairman of the Board, a shareholder resolution to the board to conduct a thorough search for candidates and appoint at least 2 other independent, qualified directors to the board promptly after the meeting, shareholder resolution to the Board to conduct a thorough search for candidates and appoint at least two other independent, highly qualified Directors to the Board promptly after the meeting, at the annual meeting of shareholders scheduled to be held on July 12, 2023.お知らせ • Jun 21Jonathan Milner Sends a Letter to Abcam plcOn June 20, 2023, Jonathan Milner sent a letter to Abcam plc, requesting the Company to 1) confirm that holders of uninstructed ADSs shall not be deemed to have instructed the Depositary to give a discretionary proxy to a person designated by the Company to vote the Deposited Securities at the EGM, and further, that Deposited Securities represented by ADSs for which no timely voting instructions are received from the Holder shall not be voted at the July 12, 2023 extraordinary general meeting of the Company, 2) pursuant to Section 116 and 118 of the Companies Act of 2006, for the Company to deliver equity holder records, 3) pursuant to sections 116(2) and (3) of the Act, seeking a copy of the register of members, held by the Company pursuant to Section 113 of the Act, pursuant to section 811(2) and (3) of the Act, seeking a copy of all of the entries in the register of interests held by the Company pursuant to Section 808 of the Act as of June 9, 2023 and 4) ask that the Company confirm now that it will recognize any and all proxies delivered and votes cast in connection with the upcoming general meeting where the intention of the shareholder voting is clear. In addition, Jonathan Milner urged the shareholders to vote for all his 8 proposals at the extraordinary general meeting, scheduled to be held on July 12, 2023.お知らせ • Jun 13Jonathan Milner issues Open Letter to shareholders of Abcam plcOn June 12, 2023, Jonathan Milner announced that he has sent an open letter to shareholders of Abcam plc stating that he has attempted to meaningfully engage with board members on multiple occasions where he offered to help reverse the Company’s loss of focus and he was offered a board seat subject to restrictions that would impair his ability to hold management accountable and to serve shareholders effectively. In addition, Jonathan Milner stated that current board has lost focus on governance, execution, and cost control, board current Board has lost focus on governance, execution, and cost control, changing targets mask underperformance, failed to execute the 5-year plan, stated the board requires accountability to shareholders and outlines his plan to restore shareholder trust and value and make Company the world leading antibody Company once again. Further, Jonathan Milner urged the shareholders to vote for the removal of Peter Allen, Michael Baldock, Sally Crawford, the election of Jonathan Milner as a director and appointment as executive chairman of the board, at the 2023 annual meeting of shareholders.お知らせ • May 31Jonathan Milner Calls Extraordinary General Meeting to Replace Directors at AbcamOn May 30, 2023, Jonathan Milner delivered to Abcam plc a notice pursuant to Sections 303 and 304 of the United Kingdom Companies Act of 2006 compelling the Company to call an extraordinary general meeting of shareholders of the Company, to consider proposals that: (1) Peter Allen, Sally W. Crawford, and Michael S. Baldock be removed from office as directors of the Company; (2) any director appointed after the Company’s receipt of this requisition and before the occurrence of the meeting it requires shall be removed from office as a director of the Company; (3) Jonathan Milner be appointed as Executive Chairman of the Board; (4) the Board should conduct a thorough search for candidates and appoint at least 2 other independent Directors to the Board promptly after the meeting; and (5) the Company shall reimburse expenses incurred by Jonathan Milner and others in connection with the foregoing matters.お知らせ • May 06Abcam plc Reiterates Earnings Guidance for the Years 2023 and 2024Abcam plc reiterated earnings guidance for the years 2023 and 2024. For the year 2023, the company reiterates its reported revenue guidance of approximately £420 million to £440 million, representing 15% to 20% constant exchange rate revenue growth.The company is reiterating its 2024 revenue goals of £450 million to £525 million with adjusted operating profit margins of greater than 30%.お知らせ • Jan 31Abcam plc Provides Revenue Guidance for the Fiscal Year 2023Abcam plc provided revenue guidance for the fiscal year 2023. For the fiscal year 2023, the company anticipates 15% to 20% constant exchange rate revenue growth from fiscal year 2022's total reported revenues of approximately 360 million.Seeking Alpha • Sep 29Abcam: A Good Growth Stock In The Healthcare MarketSummary I will update my previously published article on Abcam from 15 months ago. Readers will have the opportunity to learn about interim events with the company. I will suggest how a new investor should start a position in the stock.Seeking Alpha • Sep 12Abcam ADS Non-GAAP EPS of 14.00p, revenue of £185.2MAbcam ADS press release (NASDAQ:ABCM): 1H Non-GAAP EPS of 14.00p. Revenue of £185.2M (+23.3% Y/Y). "For the full year ending December 2022, we currently estimate total revenue to increase ~20% CER including the impact from the acquisition of BioVision, with organic CER growth of mid-teens. We expect the contribution from the sale of higher margin in-house products and the full year effect of BioVision to contribute to a continuing increase in adjusted operating margins. "We remain committed to generating revenue of £450 – 525m for the year ending 31 December 2024 (calculated at the average exchange rates for the 12 months ended June 2021)."Seeking Alpha • Jul 09Abcam: A Promising Business Model In The Drug IndustryI will outline the history of drug development. Information for the Abcam business model will be outlined for my readers. As a secondary model for my readers, I will cite Syneos Health, Inc.収支内訳Abcam の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史NasdaqGS:ABCM 収益、費用、利益 ( )GBP Millions日付収益収益G+A経費研究開発費30 Jun 2338031803631 Mar 23371-31823531 Dec 22362-81843530 Sep 22356-11813330 Jun 2235071783231 Mar 2233361682831 Dec 2131541572430 Jun 21298161532531 Mar 2128471442331 Dec 20295261472730 Sep 2026551252030 Jun 20260131323831 Mar 20267271212231 Dec 19273431021230 Sep 1926744961130 Jun 1926044961531 Mar 1925351891231 Dec 1824558881430 Sep 1823960831530 Jun 1823362781631 Mar 1823059791831 Dec 1722755811930 Sep 1722249801930 Jun 1721742791931 Mar 1720641721831 Dec 1619640661730 Sep 1618439631630 Jun 1617237591431 Mar 1616437551331 Dec 1515637521230 Sep 1515037491130 Jun 1514437461031 Mar 1513836421031 Dec 1413335391030 Sep 1413035381030 Jun 1412834371031 Mar 141273437931 Dec 131273437830 Sep 131253336830 Jun 131223334831 Mar 131163032731 Dec 1211028307質の高い収益: ABCMには£64.5M } という大きな 一回限りの 損失があり、過去 12 か月の財務実績が30th June, 2023に影響を及ぼしています。利益率の向上: ABCMの現在の純利益率 (0.7%)は、昨年(2.1%)よりも低くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: ABCMの収益は過去 5 年間で年間56.5%減少しました。成長の加速: ABCMは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。収益対業界: ABCMは過去 1 年間で収益成長率がマイナス ( -65.8% ) となったため、 Biotechs業界平均 ( 43% ) と比較することが困難です。株主資本利益率高いROE: ABCMの 自己資本利益率 ( 0.3% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/12/07 21:33終値2023/12/05 00:00収益2023/06/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Abcam plc 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。18 アナリスト機関Xian DengBerenbergMichael RyskinBofA Global ResearchPaul KnightBrean Capital Historical (Janney Montgomery)15 その他のアナリストを表示
お知らせ • Dec 19Abcam Files Form 15Abcam plc (Abcam Limited) has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Ordinary Shares, nominal value £0.002 per share and American Depositary Shares, each representing one Ordinary Share under the Securities Exchange Act of 1934, as amended.
お知らせ • Dec 07+ 2 more updatesAbcam plc(NasdaqGS:ABCM) dropped from NASDAQ Composite IndexAbcam plc has been dropped from NASDAQ Composite Index .
お知らせ • Oct 24Jonathan Milner Issues Statement Responding to the Glass Lewis ReportOn October 23, 2023, Jonathan Milner announced that he has issued a statement in response to a report from Glass Lewis and its observations on the disproportionate rewards for Company’s Executive Directors and on the identified issues with peer group valuation strategies. In addition, Jonathan Milner urged the shareholders to vote against the current proposed acquisition of Company by Danaher Corporation.
お知らせ • Oct 20Jonathan Milner Continues Opposition to Danaher Corporation AcquisitionOn October 18, 2023, Jonathan Milner announced that he has responded to the Institutional Shareholder Services (ISS) recommendation to vote in favour of the deal. Jonathan Milner stated that he is continuing his attempts to convince shareholders to vote against Abcam plc's $5.7bn acquisition by Danaher Corporation despite a recommendation in favour by ISS. Jonathan Milner added that his reasoning remains as it was back in August - that the sale price of $24 per share is undervaluing the Company's short-term growth potential. Jonathan Milner stated that while he maintains his willingness to see the Company go to Danaher Corporation or ‘another suitor at a fair price’, the likelihood of a tall dark stranger sweeping in should this deal fall through is low.
お知らせ • Oct 17Jonathan Milner Releases Presentation to Abcam plc ShareholdersOn October 16, 2023, Jonathan Milner announced that he has issued a presentation covering the reasons for Abcam shareholders to vote against the $24 per share bid from Danaher Corporation. Jonathan Milner added that he believes that the Company stands as an exceptional UK asset and should not be undersold to Danaher and mentioned that he is open to selling to Danaher or another suitor at a fair price that genuinely reflects the Company’s true value and potential. Jonathan Milner stated that, in the presentation, he has unveiled his strategy for the Company and stated that he intends to convene an Extraordinary General Meeting (EGM) aimed at overhauling the Company's Board.
お知らせ • Oct 11Jonathan Milner issues Open Letter to shareholders of Abcam plcOn October 10, 2023, Jonathan Milner announced that he has issued a letter to Abcam plc’s shareholders for recently published scheme circular (Scheme Circular, as published on October 5, 2023) detailing the proposed acquisition of the Company by Danaher Corporation or its affiliates. Jonathan Milner added that he is prepared to sell to Danaher or to another bidder at the right price, provided that it accurately reflects the value and potential of the Company and stated that shareholders are not seeing the full value of the investment that the Company undertook to drive improved performance over the longer term. In addition, Jonathan Milner urged the shareholders to question the scheme circular, the unacceptable Offer price and continue to vote against the current proposed acquisition of the Company by Danaher Corporation.
お知らせ • Sep 29Jonathan Milner issues Open Letter to Shareholders of Abcam plcOn September 28, 2023, Jonathan Milner announced that he has issued open letter to the Company’s shareholders announcing his vote against campaign and providing them with the opportunity to send a clear message to the Board that the board is dissatisfied with the proposed acquisition of the Company by Danaher Corporation or its affiliates (“Danaher”) and the Company’s governance, execution and cost control.
お知らせ • Sep 15Jonathan Milner Opposes Danaher's Acquisition of AbcamOn September 14, 2023, Jonathan Milner announced his decision to vote against the proposed acquisition of Abcam by Danaher Corporation or its affiliates, his decision to oppose the acquisition is informed by feedback received from many shareholders and analysts, who share his belief that the $24 per share offer announced on August 28, 2023 by the Company substantially undervalues the Company, and when considering the potential of the Company as an independent entity with an effective Board and Executive Leadership, the proposed acquisition price falls significantly short of its inherent worth. In addition, Jonathan Milner stated that he will formally request the Company to convene an extraordinary general meeting with the purpose of replacing the Company’s board, including the current CEO, CFO and Chairman. Further, Jonathan Milner stated that he will publish a proxy statement and accompanying proxy card in due course to be used to solicit votes in support of the proposals that will be presented for shareholder vote at the proposed extraordinary annual meeting of stockholders of the Company.
お知らせ • Sep 02Abcam plc Suspends Financial Guidance for the Fiscal 2023 and Fiscal 2024Abcam plc suspended financial guidance for the fiscal 2023 and fiscal 2024. Due to the pending acquisition, financial guidance has been suspended.
お知らせ • Aug 29Danaher Corporation (NYSE:DHR) entered into definitive agreement to acquire Abcam plc (NasdaqGS:ABCM) for $5.7 billion.Danaher Corporation (NYSE:DHR) entered into definitive agreement to acquire Abcam plc (NasdaqGS:ABCM) for $5.7 billion on August 26, 2023. As per the the terms of the transaction, the offer price per share is $24 for 229,723,147 Abcam shares. Danaher expects to fund the acquisition using cash on hand and proceeds from the issuance of commercial paper. Under the Transaction Agreement, Abcam plc will be required to pay to Danaher, in cash, an amount equal to £45 million ($56.62512 million) if the transaction agreement is terminated, whereas, Danaher Corporation will pay £227 million ($285.642272 million) in case of termination. Transaction is subject to customary conditions, including receipt of applicable regulatory approvals and Abcam shareholder approval. The Transaction has been unanimously approved and recommended by the Abcam Board of Directors and unanimously approved by the Danaher Board of Directors. The transaction is anticipated to close mid-2024 . Lazard Freres & Co. LLC, Lazard & Co., Limited, Morgan Stanley & Co. International plc, acted as financial advisors and provided opinion to board of Abcam, Citibank, N.A., acted as a depository bank, Latham & Watkins (London) LLP acted as a legal advisor to Abcam. Skadden, Arps, Slate, Meagher & Flom LLP acted as a legal advisor to Danaher. Phillip R. Mills of Davis Polk advised Lazard Ltd. and Morgan Stanley as financial advisers to Abcam plc.
お知らせ • Aug 17Jonathan Milner Sends an Open Letter to Abcam plcOn August 16, 2023, Jonathan Milner announced that he has sent an open letter to Abcam plc, stating that the Company had received strategic inquiries from multiple parties over the past few weeks and the Board of Directors had unanimously decided to initiate a process to explore strategic alternatives for the business. In addition, Jonathan Milner stated that in order to give the Board the time and space to pursue the opportunities from the review, and acting in good faith, he temporarily suspended his campaign and requested removal of the EGM resolutions on June 26, 2023, he was disappointed that this offer was not acted upon and since that time have been provided with one unsatisfactory call with management, and he would like to reiterate that his offer remains in place should the board wish to accept my help with Company performance and shareholder value creation.
お知らせ • Jul 06Abcam plc Provides Revenue Guidance for the First Half Ending June 30, 2023Abcam plc provided revenue guidance for the first half ending June 30, 2023. For the period, the company expects revenues of >£203 million. First half 2023 estimated revenues grew approximately 10% on a reported basis or 5.5% on a constant exchange rate basis as compared to 20% growth on a constant exchange rate basis in the comparable prior period.
お知らせ • Jun 29Jonathan Milner Announces Suspension of Proxy SolicitationOn June 26, 2023, Jonathan Milner issued a statement regarding the upcoming extraordinary meeting of shareholders of Abcam PLC. Jonathan Milner stated that in light of reports that the Company has received credible inbound M&A interest, and the Company’s announcement that the board is pursuing these strategic alternatives, he has decided to suspend his solicitation for the time being to allow the board to focus on pursuing its strategic review and thereby create maximum shareholder value. Jonathan Milner added that he remains willing to join the board immediately, either as Executive Chairman, Chairman or a Non-Executive Director, if invited to assist and support it in the strategic review process to obtain a full and fair price but will not agree to any standstill restrictions that would impair his ability to hold the board accountable by calling for another EGM or nominating directors at the next AGM.
お知らせ • Jun 28Abcam plc Provides Revenue Guidance for Fy2023 and Fy2024Abcam plc provided revenue guidance for FY2023 and FY2024. The Company reiterates its FY2023 guidance of reported revenue of approximately £420 million to £440 million, representing 15% to 20% constant exchange rate revenue growth.For FY2024, reported revenue of approximately £475 million to £525 million1, representing 11.3% to 13.4% CER revenue CAGR2 and 10.0% to 12.1% organic revenue CAGR3 from FY2019.
お知らせ • Jun 22Jonathan Milner Issues an Open Letter to shareholders of Abcam plcOn June 21, 2023, Jonathan Milner announced that he has issued an open letter to shareholders of Abcam plc, in response to statements made by the Company in its statement on 20 June 2023, outlines the Company’s lack of focus and his plan to restore the Company’s financials, accountability, and executional discipline. In addition, Jonathan Milner stating that as a reminder the deadline for ADS shareholders to record your proxy vote is 10am EST on6 July 2023, stated it his open letter that time for change is now, the Company interest in M&A, his 6-month plan for Company’s value creation. Further, Jonathan Milner urged the shareholders to vote for removal of Peter Allen, Michael Baldock, and Sally Crawford, from the Company board, election of Jonathan Milner as a Director and appointment as Executive Chairman of the Board, a shareholder resolution to the board to conduct a thorough search for candidates and appoint at least 2 other independent, qualified directors to the board promptly after the meeting, shareholder resolution to the Board to conduct a thorough search for candidates and appoint at least two other independent, highly qualified Directors to the Board promptly after the meeting, at the annual meeting of shareholders scheduled to be held on July 12, 2023.
お知らせ • Jun 21Jonathan Milner Sends a Letter to Abcam plcOn June 20, 2023, Jonathan Milner sent a letter to Abcam plc, requesting the Company to 1) confirm that holders of uninstructed ADSs shall not be deemed to have instructed the Depositary to give a discretionary proxy to a person designated by the Company to vote the Deposited Securities at the EGM, and further, that Deposited Securities represented by ADSs for which no timely voting instructions are received from the Holder shall not be voted at the July 12, 2023 extraordinary general meeting of the Company, 2) pursuant to Section 116 and 118 of the Companies Act of 2006, for the Company to deliver equity holder records, 3) pursuant to sections 116(2) and (3) of the Act, seeking a copy of the register of members, held by the Company pursuant to Section 113 of the Act, pursuant to section 811(2) and (3) of the Act, seeking a copy of all of the entries in the register of interests held by the Company pursuant to Section 808 of the Act as of June 9, 2023 and 4) ask that the Company confirm now that it will recognize any and all proxies delivered and votes cast in connection with the upcoming general meeting where the intention of the shareholder voting is clear. In addition, Jonathan Milner urged the shareholders to vote for all his 8 proposals at the extraordinary general meeting, scheduled to be held on July 12, 2023.
お知らせ • Jun 13Jonathan Milner issues Open Letter to shareholders of Abcam plcOn June 12, 2023, Jonathan Milner announced that he has sent an open letter to shareholders of Abcam plc stating that he has attempted to meaningfully engage with board members on multiple occasions where he offered to help reverse the Company’s loss of focus and he was offered a board seat subject to restrictions that would impair his ability to hold management accountable and to serve shareholders effectively. In addition, Jonathan Milner stated that current board has lost focus on governance, execution, and cost control, board current Board has lost focus on governance, execution, and cost control, changing targets mask underperformance, failed to execute the 5-year plan, stated the board requires accountability to shareholders and outlines his plan to restore shareholder trust and value and make Company the world leading antibody Company once again. Further, Jonathan Milner urged the shareholders to vote for the removal of Peter Allen, Michael Baldock, Sally Crawford, the election of Jonathan Milner as a director and appointment as executive chairman of the board, at the 2023 annual meeting of shareholders.
お知らせ • May 31Jonathan Milner Calls Extraordinary General Meeting to Replace Directors at AbcamOn May 30, 2023, Jonathan Milner delivered to Abcam plc a notice pursuant to Sections 303 and 304 of the United Kingdom Companies Act of 2006 compelling the Company to call an extraordinary general meeting of shareholders of the Company, to consider proposals that: (1) Peter Allen, Sally W. Crawford, and Michael S. Baldock be removed from office as directors of the Company; (2) any director appointed after the Company’s receipt of this requisition and before the occurrence of the meeting it requires shall be removed from office as a director of the Company; (3) Jonathan Milner be appointed as Executive Chairman of the Board; (4) the Board should conduct a thorough search for candidates and appoint at least 2 other independent Directors to the Board promptly after the meeting; and (5) the Company shall reimburse expenses incurred by Jonathan Milner and others in connection with the foregoing matters.
お知らせ • May 06Abcam plc Reiterates Earnings Guidance for the Years 2023 and 2024Abcam plc reiterated earnings guidance for the years 2023 and 2024. For the year 2023, the company reiterates its reported revenue guidance of approximately £420 million to £440 million, representing 15% to 20% constant exchange rate revenue growth.The company is reiterating its 2024 revenue goals of £450 million to £525 million with adjusted operating profit margins of greater than 30%.
お知らせ • Jan 31Abcam plc Provides Revenue Guidance for the Fiscal Year 2023Abcam plc provided revenue guidance for the fiscal year 2023. For the fiscal year 2023, the company anticipates 15% to 20% constant exchange rate revenue growth from fiscal year 2022's total reported revenues of approximately 360 million.
Seeking Alpha • Sep 29Abcam: A Good Growth Stock In The Healthcare MarketSummary I will update my previously published article on Abcam from 15 months ago. Readers will have the opportunity to learn about interim events with the company. I will suggest how a new investor should start a position in the stock.
Seeking Alpha • Sep 12Abcam ADS Non-GAAP EPS of 14.00p, revenue of £185.2MAbcam ADS press release (NASDAQ:ABCM): 1H Non-GAAP EPS of 14.00p. Revenue of £185.2M (+23.3% Y/Y). "For the full year ending December 2022, we currently estimate total revenue to increase ~20% CER including the impact from the acquisition of BioVision, with organic CER growth of mid-teens. We expect the contribution from the sale of higher margin in-house products and the full year effect of BioVision to contribute to a continuing increase in adjusted operating margins. "We remain committed to generating revenue of £450 – 525m for the year ending 31 December 2024 (calculated at the average exchange rates for the 12 months ended June 2021)."
Seeking Alpha • Jul 09Abcam: A Promising Business Model In The Drug IndustryI will outline the history of drug development. Information for the Abcam business model will be outlined for my readers. As a secondary model for my readers, I will cite Syneos Health, Inc.